id: sud_medication_treatment_rate_oud_to_NEW:congenital_malformation_risk
name: OUD Medication Treatment Rate â†’ Major Congenital Malformation Risk
from_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: OUD Medication Treatment Rate
to_node:
  node_id: NEW:congenital_malformation_risk
  node_name: Major Congenital Malformation Risk
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Access to medication-assisted treatment for OUD during pregnancy provides stable pharmacotherapy'
- 'Step 2: Buprenorphine-based treatments (with or without naloxone) maintain maternal stability without
  increased teratogenic risk'
- 'Step 3: No difference in major congenital malformation rates between combination and monotherapy'
- 'Step 4: Expanding treatment options does not compromise fetal safety regarding birth defects'
- 'Step 5: Both formulations demonstrate comparable safety profiles for structural birth outcomes'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Loreen Straub et al. 2024. "Comparative Safety of In Utero Exposure to Buprenorphine
    Combined With Naloxone vs Buprenorphine Alone.." https://doi.org/10.1001/jama.2024.11501
  supporting_citations:
  - Additional citations require full-text access - Abstract references limited perinatal safety data
    on combination product
  - Additional citations require full-text access - Study builds on existing buprenorphine monotherapy
    pregnancy research
  - Additional citations require full-text access - Medicaid utilization data from 2000-2018 analyzed
  doi: 10.1001/jama.2024.11501
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: No differences were observed in major congenital malformations between buprenorphine-naloxone
  and buprenorphine alone exposures, supporting equivalent safety of both treatment formulations.
quantitative_effects:
  sample_size: 8695
structural_competency:
  equity_implications: This null finding is critically important for structural policy. Historical guidelines
    restricting combination product in pregnancy were based on limited safety data, creating structural
    barriers to treatment. Evidence of comparable safety supports policy changes that increase treatment
    flexibility and access for pregnant individuals with OUD.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.687100'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
